| scholarly article | Q13442814 |
| P356 | DOI | 10.1046/J.1537-2995.1991.31591263191.X |
| P698 | PubMed publication ID | 2048176 |
| P2093 | author name string | Bishop JF | |
| Matthews JP | |||
| McGrath K | |||
| Wolf MM | |||
| Yuen K | |||
| Szer J | |||
| P433 | issue | 5 | |
| P921 | main subject | platelet transfusion | Q23925170 |
| P304 | page(s) | 392-396 | |
| P577 | publication date | 1991-06-01 | |
| P1433 | published in | Transfusion | Q15758500 |
| P1476 | title | Factors influencing 20-hour increments after platelet transfusion | |
| P478 | volume | 31 |
| Q50542143 | A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. |
| Q33366635 | Assessing the effectiveness of whole blood-derived platelets stored as a pool: a randomized block noninferiority trial |
| Q33333390 | Clinical and laboratory factors that affect the post-transfusion platelet increment |
| Q33329515 | Clinical consequences of alterations in platelet transfusion dose: a prospective, randomized, double-blind trial |
| Q33340006 | Design of clinical trials to evaluate the efficacy of platelet transfusion: the euroSPRITE trial for components treated with Helinx technology. |
| Q33441106 | Extended Small-Dose Platelet Transfusions in Multitransfused Hemato-Oncological Patients: A Single-Center Experience |
| Q47575948 | Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation |
| Q33340623 | Failing to live up to the fanfare? A personal perspective on obstacles to the clinical development of thrombopoietic agents |
| Q47444445 | Incidence and specificity of HLA antibodies in multitransfused patients with acquired aplastic anemia |
| Q33489533 | Ineffectiveness of platelet transfusions in the course of thrombocytopenia of central origin. Work Group coordinated by ANDEM |
| Q33497804 | Influence of antibiotics on posttransfusion platelet increment. |
| Q48283082 | Linear decline of corrected platelet count increment within 24 hours after platelet transfusion in haematological patients: A prospective observational study |
| Q33337229 | Lowering the prophylactic platelet transfusion threshold: a prospective analysis |
| Q46115563 | Meta‐analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen‐reduced platelets |
| Q33380740 | Modification of solid phase red cell adherence assay for the detection of platelet antibodies in patients with thrombocytopenia |
| Q33396720 | Pathogen-inactivation of platelet components with the INTERCEPT Blood System ™: a cohort study |
| Q90217546 | Platelet Transfusion: And Update on Challenges and Outcomes |
| Q33488022 | Platelet support and the use of cytokines |
| Q33398221 | Platelet transfusion alters CD40L blood level and release capacity in patients suffering from thrombocytopenia |
| Q40512641 | Platelet transfusion refractoriness--prevention and therapeutical approaches |
| Q56505470 | Platelet transfusions |
| Q74527927 | Platelet-bound immunogloblins before and after platelet transfusion: measurement of in vivo binding |
| Q34988663 | Recommendations for the transfusion management of patients in the peri-operative period. II. The intra-operative period |
| Q37209117 | Recommendations for the transfusion of plasma and platelets |
| Q33347819 | Refractoriness to platelet transfusions |
| Q33394967 | Safety and clinical efficacy of platelet components prepared with pathogen inactivation in routine use for thrombocytopenic patients |
| Q48623928 | Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity |
| Q33350432 | The definition of refractoriness to platelet transfusions |
| Q33492420 | The efficacy of leukodepletion to improve platelet transfusion response: a critical appraisal of clinical studies. |
| Q30305594 | The evaluation and management of platelet refractoriness and alloimmunization |
| Q33328580 | The reduction of HLA class I expression on platelets: a potential approach in the management of HLA-alloimmunized refractory patients |
| Q33196131 | The value of alloantibody detection in predicting response to HLA-matched platelet transfusions |
| Q33368170 | Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. |
| Q33490485 | Therapeutic support of the patient with thrombocytopenia. |
| Q33492585 | Thrombocytopenia. Issues in diagnosis and therapy. |
Search more.